EXPAND
COLLAPSE
+
Annual Report 2005
Overview
Who we are
About Novo Nordisk
Management
Management structure
Corporate governance
Ownership
Facts and figures
Global offices
Products and services
Research & development (Pipeline)
History
What we do
Diabetes care
Haemostasis management
Growth hormone therapy
HRT
How we perform
Access to health
Diabetes care
Haemophilia management
Socio Economics
Animal welfare
Awards and recognitions
Bioethics
Business ethics
Climate change
Clinical trials
Community engagement
TakeAction!
Donations
Compliance
Economic footprint
Environmental management
Environmental footprint
Green accounts
Equal opportunities
Financial performance
Download
Financial highlights
Conference call
R & D pipeline
The share
Contact IR
Genetic enginering
Health and safety
Human rights
Interactive charts
Interactive charts
Key performance data
Key performance indicators
Legal preecedings
Public policy activities
Oxford Health Alliance
Quality
Stem cell research
Supply chain management
Workplace quality
People strategy
NovoSund
How we work
Accounting for performance
Business cases
Product stewardship
US Business case
Environmentally sound design
Business strategy
Globalisation
Risk management
Changing diabetes
Codes, standards and practices
Definitions
Non-financial
Financial
Key challenges
Stakeholder engagement
Partnerships
Memberships
Sustainability
The Novo Nordisk Way
Triple Bottom Line
How we are accountable
Audit and assurance
Accounting policies
Independence Statement
Auditors' reports
Guide to assurance statement
Reporting challenges
What assures?
Materiality
GRI
11 Principles
GRI Index
Vision and Strategy
Profile
Governance structure and Managment Systems
Performance indicators
Economic
Environmental
Social
Labour practicies
Product responsibility
Society
Global Compact
Communication on progress
Stakeholder feedback
CLOSE